Fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy
Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it...
Saved in:
Published in | Therapeutic advances in neurological disorders Vol. 18; p. 17562864251325338 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
SAGE Publications
01.01.2025
SAGE Publishing |
Subjects | |
Online Access | Get full text |
ISSN | 1756-2864 1756-2856 1756-2864 |
DOI | 10.1177/17562864251325338 |
Cover
Loading…
Abstract | Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy
Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship.
What did the researchers do? The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period.
What did the researchers find? A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness.
What do the findings mean? This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance. |
---|---|
AbstractList | Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy
Why was the study done?
Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship.
What did the researchers do?
The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period.
What did the researchers find?
A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness.
What do the findings mean?
This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance. Background: Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression. Objectives: This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms. Methods: We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance. Results: A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094–3.583, p = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29–3.729, p = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance ( P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality. Conclusion: Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake. Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression. This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms. We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance. A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583, = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729, = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance ( for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality. Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake. Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy Why was the study done? Complaints of fatigue and poor sleep quality are common in patients with epilepsy. A crucial problem related to fatigue is that it may precipitate a single or multiple seizures. Patients with poor sleep quality also have high seizures frequency and depression symptoms. We wondered whether patients with fatigue or poor sleep quality have higher risk of developing resistance to anti-seizure medication. We also investigate the role of depression symptoms in the relationship. What did the researchers do? The research team invited patients with newly diagnosed epilepsy to participate in this study in Northeast China. The participants were asked to complete questionnaires to assess fatigue, sleep quality and depression symptoms. Then the participants were treated with anti-seizure medications. The researchers observed how the patients responded to the anti-seizure medications over 24-month period. What did the researchers find? A total of 189 patients participated in this study. We observed that 59 patients had resistance to anti-seizure medication and 130 responded well to drugs. Patients who had fatigue were more likely to experience drug resistance. Similarly, patients who had poor sleep quality were more likely to have drug resistance. Additionally, depression symptoms play an important in the effect of fatigue and sleep quality on drug responsiveness. What do the findings mean? This study has some important findings. Patients who had fatigue or poor sleep quality were more likely to responded poorly to anti-seizure medications. We also observed the mediating role of depression severity. These findings tell us the importance of assessing fatigue, sleep quality and depression symptoms in patients with newly diagnosed epilepsy which may help identify those at greater risk of drug resistance. Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression.BackgroundComplaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have higher frequency of seizures and are more likely to have symptoms of depression.This study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms.ObjectivesThis study aims to determine the association of baseline fatigue and sleep quality with antiseizure medication (ASM) resistance in patients with newly diagnosed epilepsy (PWNDE). We also evaluate whether the association is mediated by depression symptoms.We performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance.MethodsWe performed a prospective cohort study of PWNDE at comprehensive epilepsy center in Northeast China between June 2020 and May 2024. Fatigue, sleep quality, and depression symptoms were assessed at baseline. All patients were followed for 24 months for ASM-resistant epilepsy. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) of ASM resistance. Models fitted with restricted cubic spline were performed to test for linear and nonlinear shapes of each association. Mediation analysis was used to estimate the mediating effects of depression severity on association between fatigue, sleep quality, and ASM resistance.A total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583, p = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729, p = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance (P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality.ResultsA total of 189 patients (59 ASM-resistant cases and 130 ASM-responsive controls) were included in the final analysis. Baseline fatigue (HR, 1.98; 95% confidence interval (CI), 1.094-3.583, p = 0.024) and poor sleep quality (HR, 2.193; 95% CI, 1.29-3.729, p = 0.004) were associated with an increased hazard of ASM resistance in PWNDE after full adjustments. There exists a nonlinear association between Fatigue Severity Scale score and the hazard of ASM resistance (P for nonlinear = 0.012). Depression severity partly mediated the effect of fatigue and sleep quality on ASM resistance, with mediated proportions of 18.5% for the fatigue and 23.7% for the sleep quality.Baseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake.ConclusionBaseline fatigue and poor sleep quality were associated with an increased risk of ASM resistance. The association between fatigue, sleep quality, and ASM resistance were partly mediated by depression severity. These findings emphasize that patients with ASM-resistant epilepsy are more likely to have fatigue, depression, and poor sleep quality at baseline and this may be unrelated to ASM intake. |
Author | Zhong, Rui Li, Guangjian Zhang, Xinyue Lin, Weihong Li, Nan Li, Jing Zhao, Teng |
Author_xml | – sequence: 1 givenname: Rui surname: Zhong fullname: Zhong, Rui organization: Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China – sequence: 2 givenname: Teng surname: Zhao fullname: Zhao, Teng organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China – sequence: 3 givenname: Nan surname: Li fullname: Li, Nan organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China – sequence: 4 givenname: Jing surname: Li fullname: Li, Jing organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China – sequence: 5 givenname: Guangjian surname: Li fullname: Li, Guangjian organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China – sequence: 6 givenname: Xinyue orcidid: 0000-0002-6434-5599 surname: Zhang fullname: Zhang, Xinyue organization: Department of Neurology, The First Hospital of Jilin University, Xinmin Street, No. 1, Changchun, Jilin 130021, China – sequence: 7 givenname: Weihong orcidid: 0000-0002-5904-5989 surname: Lin fullname: Lin, Weihong organization: Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40084242$$D View this record in MEDLINE/PubMed |
BookMark | eNplkk1rFTEUhoNU7If-ADeSpYt79SSZzMdKpFgtFNzoOmSSM7cpM8k0yVhG_PHm9tbS4iIkvHl4X87HKTnywSMhbxl8YKxpPrJG1rytKy6Z4FKI9gU52WvbvXj05H1MTlO6Aah5U8ErclwBtBWv-An5c6Gz2y24oWlEnOntokeX1w21OEdMyQVP0zrNOUxpQ7W35WSX0P1eItIJrTPFoEAFdilrb5A6T-cios-J3rl8TT3ejSu1Tu98SGgpzm7EOa2vyctBjwnfPNxn5OfFlx_n37ZX379enn--2pqKQ952VS2hES0YqIF3puoBOJhOtkaUygcQAqAxiGh1a3prbD8w3WsBnTGacXFGLg--NugbNUc36biqoJ26F0LcKR2zMyMqed9TZobS1IpJ07VWa13yasPaxnTF69PBa176Ur4pVUY9PjN9_uPdtdqFX4qxDiQIWRzePzjEcLtgympyyeA4ao9hSUqU0TLJC13Qd0_DHlP-za8A7ACYGFKKODwiDNR-R9R_OyL-Ajk7sF4 |
Cites_doi | 10.1111/j.1528-1167.2011.03041.x 10.1016/j.seizure.2013.05.018 10.1016/S0140-6736(18)32596-0 10.1111/epi.17155 10.1016/j.seizure.2016.11.006 10.1093/brain/awab401 10.1016/j.yebeh.2019.106661 10.1007/s11136-005-4346-x 10.1016/S1474-4422(06)70415-X 10.1016/j.yebeh.2022.108688 10.1111/epi.17564 10.1007/s11136-015-1056-x 10.1111/epi.12550 10.1016/j.neubiorev.2016.05.008 10.1016/j.seizure.2020.04.003 10.1111/j.1528-1167.2009.02397.x 10.1016/j.expneurol.2007.09.026 10.1016/0165-1781(89)90047-4 10.1016/j.comppsych.2016.08.004 10.1016/j.tins.2014.06.005 10.1001/archneur.1989.00520460115022 10.1016/S0140-6736(23)01048-6 10.1146/annurev-med-052209-100430 10.1007/s13311-021-01021-w 10.1016/j.yebeh.2014.02.019 10.1016/j.smrv.2021.101466 10.1111/epi.17664 10.1111/epi.17107 10.1016/j.seizure.2015.12.003 10.1016/j.seizure.2022.10.019 10.1016/j.yebeh.2022.108565 10.1016/S1474-4422(23)00151-5 10.1016/j.seizure.2020.10.029 10.1016/j.yebeh.2023.109568 10.1016/j.smrv.2005.03.002 10.1212/WNL.0000000000200959 10.1212/WNL.0000000000209821 10.1016/j.seizure.2022.11.002 10.1111/epi.17454 10.1111/epi.13709 10.1016/j.yebeh.2017.04.030 10.1111/j.1528-1167.2008.01902.x 10.1016/j.sleep.2018.05.010 10.1001/jama.2022.3880 10.1097/WNP.0000000000000806 10.1212/WNL.0b013e3181f25b16 10.1016/j.smrv.2022.101689 10.1111/epi.13651 10.1016/j.yebeh.2015.03.012 10.1111/epi.17710 10.1111/epi.17661 10.1111/epi.13741 10.1038/s41398-022-02297-y 10.1007/s00415-018-8971-z |
ContentType | Journal Article |
Copyright | The Author(s), 2025. The Author(s), 2025 2025 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
Copyright_xml | – notice: The Author(s), 2025. – notice: The Author(s), 2025 2025 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.1177/17562864251325338 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: Acceso a contenido Full Text - Doaj url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-2864 |
ExternalDocumentID | oai_doaj_org_article_5175621cf425415c98daaa0026c187c9 PMC11905035 40084242 10_1177_17562864251325338 |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; grantid: no.LCPYJJ2017006 – fundername: ; grantid: no. YDZJ202201ZYTS040 |
GroupedDBID | --- -TM 01A 0R~ 123 18M 29Q 4.4 53G 54M 5VS 7X7 8FI 8FJ AABMB AADUE AAKDD AAQDB AARDL AARIX AASGM AAYXX ABAWP ABEIX ABFWQ ABJIS ABKRH ABNCE ABQXT ABRHV ABUWG ABVFX ACARO ACDSZ ACDXX ACGFS ACHEB ACOFE ACROE ACRPL ADBBV ADEBD ADNMO ADOGD ADYCS ADZZY AENEX AEQLS AERKM AEUHG AEWDL AEXNY AFCOW AFEET AFKRA AFKRG AFRWT AFUIA AFWMB AGNHF AGQPQ AHHFK AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ARTOV ASPBG AUTPY AUVAJ AVWKF AYAKG AZFZN B8M BAWUL BCNDV BDDNI BENPR BKSCU BPHCQ BSEHC BVXVI CAG CCPQU CDWPY CFDXU CITATION COF CS3 DC- DC. DIK DOPDO E3Z EBS EJD EMOBN F5P FEDTE FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 H13 HMCUK HVGLF HYE HZ~ J8X K.F N9A O9- OK1 P.B PHGZM PHGZT PIMPY PQQKQ PSYQQ ROL RPM S01 SAUOL SCDPB SCNPE SFC UKHRP ZONMY ZPPRI ZRKOI ZSSAH M4V NPM 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c420t-946507380c06029c4b0020c958c3513f033007ceeeda8cbdcdbf1aba309cca123 |
IEDL.DBID | DOA |
ISSN | 1756-2864 1756-2856 |
IngestDate | Wed Aug 27 01:23:10 EDT 2025 Thu Aug 21 18:34:19 EDT 2025 Thu Sep 04 23:06:38 EDT 2025 Wed Mar 19 01:28:47 EDT 2025 Tue Aug 05 11:59:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | PWNDE ASM resistance depression symptoms fatigue sleep quality |
Language | English |
License | The Author(s), 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c420t-946507380c06029c4b0020c958c3513f033007ceeeda8cbdcdbf1aba309cca123 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6434-5599 0000-0002-5904-5989 |
OpenAccessLink | https://doaj.org/article/5175621cf425415c98daaa0026c187c9 |
PMID | 40084242 |
PQID | 3177152905 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_5175621cf425415c98daaa0026c187c9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11905035 proquest_miscellaneous_3177152905 pubmed_primary_40084242 crossref_primary_10_1177_17562864251325338 |
PublicationCentury | 2000 |
PublicationDate | 2025-01-01 |
PublicationDateYYYYMMDD | 2025-01-01 |
PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Sage UK: London, England |
PublicationTitle | Therapeutic advances in neurological disorders |
PublicationTitleAlternate | Ther Adv Neurol Disord |
PublicationYear | 2025 |
Publisher | SAGE Publications SAGE Publishing |
Publisher_xml | – name: SAGE Publications – name: SAGE Publishing |
References | e_1_3_5_27_2 e_1_3_5_25_2 e_1_3_5_23_2 e_1_3_5_21_2 e_1_3_5_44_2 e_1_3_5_46_2 e_1_3_5_48_2 e_1_3_5_29_2 e_1_3_5_40_2 e_1_3_5_42_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_3_2 e_1_3_5_5_2 e_1_3_5_39_2 Wang Y-Q (e_1_3_5_51_2) 2018; 16 e_1_3_5_16_2 e_1_3_5_37_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_35_2 e_1_3_5_10_2 e_1_3_5_33_2 e_1_3_5_54_2 e_1_3_5_56_2 e_1_3_5_18_2 e_1_3_5_50_2 e_1_3_5_52_2 e_1_3_5_31_2 e_1_3_5_28_2 e_1_3_5_26_2 e_1_3_5_24_2 e_1_3_5_22_2 e_1_3_5_43_2 e_1_3_5_45_2 e_1_3_5_47_2 e_1_3_5_49_2 e_1_3_5_2_2 e_1_3_5_41_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_4_2 e_1_3_5_6_2 e_1_3_5_17_2 e_1_3_5_38_2 e_1_3_5_15_2 e_1_3_5_36_2 e_1_3_5_13_2 e_1_3_5_34_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_55_2 e_1_3_5_19_2 e_1_3_5_53_2 e_1_3_5_30_2 |
References_xml | – ident: e_1_3_5_23_2 doi: 10.1111/j.1528-1167.2011.03041.x – ident: e_1_3_5_11_2 doi: 10.1016/j.seizure.2013.05.018 – ident: e_1_3_5_2_2 doi: 10.1016/S0140-6736(18)32596-0 – ident: e_1_3_5_21_2 doi: 10.1111/epi.17155 – ident: e_1_3_5_8_2 doi: 10.1016/j.seizure.2016.11.006 – ident: e_1_3_5_7_2 doi: 10.1093/brain/awab401 – ident: e_1_3_5_16_2 doi: 10.1016/j.yebeh.2019.106661 – ident: e_1_3_5_33_2 doi: 10.1007/s11136-005-4346-x – ident: e_1_3_5_29_2 doi: 10.1016/S1474-4422(06)70415-X – ident: e_1_3_5_25_2 doi: 10.1016/j.yebeh.2022.108688 – ident: e_1_3_5_6_2 doi: 10.1111/epi.17564 – ident: e_1_3_5_32_2 doi: 10.1007/s11136-015-1056-x – ident: e_1_3_5_20_2 doi: 10.1111/epi.12550 – ident: e_1_3_5_40_2 doi: 10.1016/j.neubiorev.2016.05.008 – ident: e_1_3_5_50_2 doi: 10.1016/j.seizure.2020.04.003 – ident: e_1_3_5_35_2 doi: 10.1111/j.1528-1167.2009.02397.x – ident: e_1_3_5_44_2 doi: 10.1016/j.expneurol.2007.09.026 – ident: e_1_3_5_27_2 doi: 10.1016/0165-1781(89)90047-4 – ident: e_1_3_5_52_2 doi: 10.1016/j.comppsych.2016.08.004 – ident: e_1_3_5_48_2 doi: 10.1016/j.tins.2014.06.005 – ident: e_1_3_5_26_2 doi: 10.1001/archneur.1989.00520460115022 – ident: e_1_3_5_3_2 doi: 10.1016/S0140-6736(23)01048-6 – ident: e_1_3_5_41_2 doi: 10.1146/annurev-med-052209-100430 – ident: e_1_3_5_46_2 doi: 10.1007/s13311-021-01021-w – ident: e_1_3_5_10_2 doi: 10.1016/j.yebeh.2014.02.019 – ident: e_1_3_5_45_2 doi: 10.1016/j.smrv.2021.101466 – ident: e_1_3_5_13_2 doi: 10.1111/epi.17664 – ident: e_1_3_5_49_2 doi: 10.1111/epi.17107 – ident: e_1_3_5_9_2 doi: 10.1016/j.seizure.2015.12.003 – ident: e_1_3_5_19_2 doi: 10.1016/j.seizure.2022.10.019 – ident: e_1_3_5_47_2 doi: 10.1016/j.yebeh.2022.108565 – ident: e_1_3_5_5_2 doi: 10.1016/S1474-4422(23)00151-5 – ident: e_1_3_5_38_2 doi: 10.1016/j.seizure.2020.10.029 – ident: e_1_3_5_39_2 doi: 10.1016/j.yebeh.2023.109568 – ident: e_1_3_5_12_2 doi: 10.1016/j.smrv.2005.03.002 – ident: e_1_3_5_28_2 doi: 10.1212/WNL.0000000000200959 – ident: e_1_3_5_55_2 doi: 10.1212/WNL.0000000000209821 – ident: e_1_3_5_17_2 doi: 10.1016/j.seizure.2022.11.002 – ident: e_1_3_5_56_2 doi: 10.1111/epi.17454 – ident: e_1_3_5_22_2 doi: 10.1111/epi.13709 – ident: e_1_3_5_36_2 doi: 10.1016/j.yebeh.2017.04.030 – ident: e_1_3_5_42_2 doi: 10.1111/j.1528-1167.2008.01902.x – ident: e_1_3_5_53_2 doi: 10.1016/j.sleep.2018.05.010 – ident: e_1_3_5_4_2 doi: 10.1001/jama.2022.3880 – volume: 16 start-page: 5 year: 2018 ident: e_1_3_5_51_2 article-title: The mutual interaction between sleep and epilepsy on the neurobiological basis and therapy publication-title: Curr Neuropharmacol – ident: e_1_3_5_24_2 doi: 10.1097/WNP.0000000000000806 – ident: e_1_3_5_43_2 doi: 10.1212/WNL.0b013e3181f25b16 – ident: e_1_3_5_14_2 doi: 10.1016/j.smrv.2022.101689 – ident: e_1_3_5_31_2 doi: 10.1111/epi.13651 – ident: e_1_3_5_34_2 doi: 10.1016/j.yebeh.2015.03.012 – ident: e_1_3_5_30_2 doi: 10.1111/epi.17710 – ident: e_1_3_5_15_2 doi: 10.1111/epi.17661 – ident: e_1_3_5_18_2 doi: 10.1111/epi.13741 – ident: e_1_3_5_54_2 doi: 10.1038/s41398-022-02297-y – ident: e_1_3_5_37_2 doi: 10.1007/s00415-018-8971-z |
SSID | ssj0062740 |
Score | 2.3460398 |
Snippet | Association between fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy
Why was the... Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep quality have... Background: Complaints of fatigue and poor sleep quality are common in patients with epilepsy. Fatigue may precipitate seizures, and patients with poor sleep... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 17562864251325338 |
SubjectTerms | Original Research |
Title | Fatigue, sleep quality, depression symptoms, and antiseizure medication resistance in patients with newly diagnosed epilepsy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40084242 https://www.proquest.com/docview/3177152905 https://pubmed.ncbi.nlm.nih.gov/PMC11905035 https://doaj.org/article/5175621cf425415c98daaa0026c187c9 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB3SBEovIW3axk27qJBTWVP5Q5Z0bEqWUEgopYG9GXkktwuJ18S7hw358R3J3iXbFnLJwRdb2GJmrHmjGb0BODGZqFNeYCwKZSlAkTbWhcxjm0jjjCoMhkNhF5fF-VX-bSqmD1p9-Zqwnh64F9xnQf6tSBOsybjI2aBW1hjjQwdMlMRwdI983jqY6tdg31BmncP09ErhHYqgtqDgiwCO2vJCgaz_fwjz70LJB55ncgD7A2RkX_qpvoQd17yC5xdDUvwQ7ick3V9LN2bdtXMt689JrsZsU-XasG510y7mN92YmcbS5Vswz-6Wt46F5HpQD6PBHk2SGbBZwwbG1Y75rVpG6Pt6xWxfmOcscy0tJ223eg1Xk7OfX8_joalCjHnKF7HOCZPJTHHkBU815t5Nc9RCYUbSqXmWEWwg1-msUVhZtFWdmMpkXJOyyc-9gd1m3rgjYFjwSlY1rRHax1lcSUcGwdGgoLgRdQSf1kIu2547o0wGevF_NBLBqVfDZqCnvQ43yBjKwRjKx4whgo9rJZb0m_jch2ncfNmVBJMkQRXNRQRve6VuPpX7pgIEVSJQW-remsv2k2b2O1BxJ4SnBM_Eu6eY_TG8SH134bDB8x52F7dL94Egz6IawTM5lSPYOz27_P5jFGz9D43UAW4 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fatigue%2C+sleep+quality%2C+depression+symptoms%2C+and+antiseizure+medication+resistance+in+patients+with+newly+diagnosed+epilepsy&rft.jtitle=Therapeutic+advances+in+neurological+disorders&rft.au=Zhong%2C+Rui&rft.au=Zhao%2C+Teng&rft.au=Li%2C+Nan&rft.au=Li%2C+Jing&rft.date=2025-01-01&rft.issn=1756-2864&rft.eissn=1756-2864&rft.volume=18&rft_id=info:doi/10.1177%2F17562864251325338&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_17562864251325338 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-2864&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-2864&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-2864&client=summon |